

Study SCI-Ta1-NSCLC-CHEMO-P2-001

Week's Newsletter

Generated by CD Pharma Group s.r.l. on 10JUL2017

Enrolment Period

START Date	END Date
01/02/2017	01/10/2017

Enrolment Status

Centre	SIV Date	Screened Patients (*)	SCR Failure Patients (**)	Randomized Patients (***)
Albano Laziale	03mar2017	1	0	1
Frosinone	17may2017	0	0	0
Milano	18may2017	0	0	0
Roma Campus Biomedico	01jun2017	0	0	0
Roma Forlanini	to be determined	0	0	0
Roma Gemelli	to be determined	0	0	0
Roma Sant Andrea	21dec2016	3	0	3
Roma Tor Vergata	to be determined	0	0	0
Total		4	0	4

Patients by Randomization Group

Treatment	N
Control Group	3
Thymosin alpha 1	1

(*): Patients who have signed Informed Consent form

(**): Patients Screened but for which one or more Inclusion and/or Exclusion Criteria are not satisfied

(***): Patients Screened and for which all Inclusion and Exclusion Criteria are satisfied

Study SCI-Ta1-NSCLC-CHEMO-P2-001

Week's Newsletter

Generated by CD Pharma Group s.r.l. on 10JUL2017

